Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

RZLT

Rezolute Inc

Feb 11 • 04:00PM ET

3.37

+0.30 9.77 %

Healthcare • Biotechnology • USA • NASD

Peers: ASND KRYS SWTX LGND RAPT SVRA IMTX UBX RKDA

| Held by: XBI IWM VTI VXF IWO SCHA VTWO IWC VHT BBC

Index	RUT	P/E	-	EPS (ttm)	-0.93	Insider Own	20.39%	Shs Outstand	91.04M	Perf Week	15.81%
Market Cap	312.49M	Forward P/E	-	EPS next Y	-0.69	Insider Trans	0.65%	Shs Float	73.82M	Perf Month	34.26%
Enterprise Value	161.75M	PEG	-	EPS next Q	-0.19	Inst Own	93.11%	Short Float	25.71%	Perf Quarter	-66.15%
Income	-77.18M	P/S	-	EPS this Y	28.54%	Inst Trans	-6.62%	Short Ratio	2.74	Perf Half Y	-45.65%
Sales	0.00M	P/B	2.08	EPS next Y	1.11%	ROA	-54.73%	Short Interest	18.98M	Perf YTD	42.80%
Book/sh	1.62	P/C	2.05	EPS next 5Y	19.83%	ROE	-59.23%	52W High	11.46 -70.58%	Perf Year	-29.50%
Cash/sh	1.64	P/FCF	-	EPS past 3/5Y	24.95% 22.65%	ROIC	-52.16%	52W Low	1.07 214.95%	Perf 3Y	21.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.43% 9.31%	Perf 5Y	-74.85%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	26.65%	Oper. Margin	-	ATR (14)	0.34	Perf 10Y	-93.87%
Dividend Ex-Date	-	Quick Ratio	15.15	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.69	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	15.15	EPS Q/Q	20.41%	SMA20	7.46%	Beta	0.52	Target Price	4.25
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-10.87%	Rel Volume	0.75	Prev Close	3.07
Employees	71	LT Debt/Eq	0.01	Earnings	Nov 06 AMC	SMA200	-43.20%	Avg Volume	6.93M	Price	3.37
IPO	May 08, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	25.68% -	Trades		Volume	5,219,763	Change	9.77%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-25	Downgrade	Wedbush	Outperform → Neutral	$1
Dec-11-25	Downgrade	Craig Hallum	Buy → Hold	$2
Dec-11-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Nov-05-24	Initiated	Wedbush	Outperform	$12
Aug-27-24	Initiated	Guggenheim	Buy	$11
Jul-17-24	Initiated	BTIG Research	Buy	$13
Jun-04-24	Initiated	Craig Hallum	Buy	$14
Apr-09-24	Initiated	Maxim Group	Buy	$8
Aug-02-22	Resumed	Canaccord Genuity	Buy	$17
Jun-15-22	Initiated	Cantor Fitzgerald	Overweight	$9
Sep-08-21	Initiated	ROTH Capital	Buy	$21
May-27-21	Initiated	Oppenheimer	Outperform	$25
May-25-21	Initiated	H.C. Wainwright	Buy	$21

Show Previous Ratings

Feb-04-26 07:00AM	Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -7.62%
Jan-14-26 11:58AM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire) +9.68%
Jan-07-26 07:00AM	Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism (GlobeNewswire) +23.04%
Dec-31-25 11:12AM	Rezolute's Phase 3 sunRIZE Study for Ersodetug Fails to Meet Primary and Secondary Endpoints Despite Analyst Backing (Insider Monkey) +7.76%
Dec-30-25 04:39PM	Insiders Made Their Bets in 2025-These Were the Top 5 Stocks They Bought (MarketBeat) -9.88%
09:30AM	Loading…
Dec-23-25 09:30AM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire) +18.05%
Dec-18-25 01:49PM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire) -7.96%
Dec-17-25 09:47AM	RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know (Zacks)
Dec-15-25 01:06PM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating RZLT Investors with Losses Encouraged to Contact the Firm (PR Newswire) -9.44%
09:35AM	Down 81.8% in 4 Weeks, Here's Why Rezolute (RZLT) Looks Ripe for a Turnaround (Zacks)
Dec-12-25 12:28PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily) +28.57%
11:52AM	Rezolute stock crashes after sole pipeline candidate fails Phase III (Clinical Trials Arena)
08:30AM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire)
05:18AM	Praxis tees up another approval filing; Geron turns to layoffs (BioPharma Dive)
Dec-11-25 07:59PM	Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure (Business Wire) -87.20%
06:41PM	Loading…
06:41PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily)
07:00AM	Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism (GlobeNewswire)
Dec-01-25 09:55AM	How Much Upside is Left in Rezolute (RZLT)? Wall Street Analysts Think 56.58% (Zacks) -5.66%
Nov-12-25 12:00PM	All You Need to Know About Rezolute (RZLT) Rating Upgrade to Buy (Zacks)
09:55AM	Can Rezolute (RZLT) Climb 49.4% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-10-25 05:30PM	Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.48%
Nov-06-25 04:05PM	Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update (GlobeNewswire) +12.08%
Nov-05-25 07:30AM	Rezolute to Host Virtual Investor Event on Ersodetug Development Program (GlobeNewswire) +5.06%
Oct-29-25 11:57AM	Is Rezolute Inc. (RZLT) One of the Top Long-Term Biotechnology Stocks to Buy (Insider Monkey)
Oct-15-25 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.89%
Oct-09-25 04:05PM	Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.34%
Sep-17-25 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire) +6.36%
07:05AM	Rezolute Stock: FDA Fast Track Fuels 2025 Breakout (MarketBeat)
Sep-02-25 07:30AM	Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism (GlobeNewswire)
Aug-27-25 07:30AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:30AM	Loading…
Aug-20-25 07:30AM	Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer (GlobeNewswire)
Aug-13-25 07:30AM	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Jul-22-25 07:30AM	Rezolute to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-09-25 07:30AM	Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) (GlobeNewswire) +6.24%
May-28-25 08:00AM	Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism (GlobeNewswire)
May-20-25 12:08PM	Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential (Insider Monkey)
May-13-25 04:05PM	Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-05-25 08:00AM	Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
May-01-25 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.32%
03:57AM	Rezolute: RZ402 Could Be A Surprise Candidate In The Making (Seeking Alpha)
Apr-25-25 04:30PM	Rezolute, Inc. Announces Closing of Underwritten Offering (GlobeNewswire)
Apr-23-25 08:05AM	Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants (GlobeNewswire) +27.65%
08:00AM	Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism ( HI ) (GlobeNewswire)
Apr-11-25 12:00PM	Rezolute (RZLT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-26-25 07:30AM	Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors (GlobeNewswire) -5.54%
Feb-12-25 04:05PM	Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-04-25 08:00AM	Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Jan-31-25 08:00AM	Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-07-25 08:00AM	Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Dec-05-24 08:00AM	Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-24 08:00AM	FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
Nov-07-24 04:05PM	Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-19-24 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update (GlobeNewswire) +5.39%
Sep-09-24 07:30AM	FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study (GlobeNewswire) +22.07%
Aug-27-24 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-05-24 07:30AM	Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
Jul-31-24 08:00AM	Rezolute to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jun-27-24 08:00AM	Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement (GlobeNewswire)
Jun-24-24 08:00AM	Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds (GlobeNewswire) +7.85%
Jun-14-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -23.45%
Jun-13-24 11:30PM	Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.84%
04:01PM	Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-30-24 08:00AM	Rezolute to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -6.33%
06:27AM	Rezolute's oral Eylea rival hits phase 2 goal, sending stock up and sparking partnership talk (FierceBiotech.com)
May-21-24 04:05PM	Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) (GlobeNewswire) +6.76%
May-15-24 10:54PM	RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024 (InvestorPlace)
04:05PM	Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-23-24 08:00AM	Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting (GlobeNewswire) -19.21%
Mar-20-24 02:33PM	Hedge Fund and Insider Trading News: Ken Griffin, Nelson Peltz, Palliser Capital, Elliott Management, Three Arrows Capital, Rezolute, Inc. (RZLT), Tesla Inc (TSLA), and More (Insider Monkey)
Mar-06-24 07:30AM	Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) (GlobeNewswire)
Feb-13-24 04:05PM	Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update (GlobeNewswire) +13.76%
Jan-24-24 08:00AM	Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer (GlobeNewswire) +6.37%
Jan-23-24 08:00AM	Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Dec-14-23 08:00AM	Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism (GlobeNewswire)
Dec-13-23 08:00AM	Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema ( DME ) (GlobeNewswire) +8.37%
Nov-24-23 11:14AM	Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an 'XBI-MAS' (Newsfile)
Nov-17-23 08:00AM	Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day (GlobeNewswire)
Nov-13-23 04:05PM	Rezolute Reports First Quarter Fiscal 2024 Results (GlobeNewswire) +12.22% -7.39%
Oct-17-23 08:00AM	Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism (GlobeNewswire) +6.52%
Oct-11-23 08:00AM	Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism (GlobeNewswire) -6.00%
Sep-14-23 04:05PM	Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Sep-06-23 07:00AM	Rezolute to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Jun-27-23 04:05PM	Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism (GlobeNewswire)
Jun-01-23 12:45PM	Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease (Newsfile) -7.51%
May-11-23 04:05PM	Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Mar-23-23 04:50PM	Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema (GlobeNewswire) -5.34%
Mar-08-23 07:00AM	Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert (GlobeNewswire) +7.44%
Feb-10-23 04:05PM	Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Dec-15-22 07:00AM	Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema (GlobeNewswire)
Nov-09-22 04:05PM	Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Nov-01-22 07:00AM	Rezolute to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-20-22 07:00AM	Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting (GlobeNewswire)
Sep-15-22 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress (GlobeNewswire)
Sep-07-22 07:00AM	Rezolute Announces Presentation at the 60th Annual ESPE Meeting (GlobeNewswire)
Aug-15-22 08:36AM	Here's What Rezolute, Inc.'s (NASDAQ:RZLT) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jun-01-22 07:00AM	Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer (GlobeNewswire)
May-12-22 04:05PM	Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress (GlobeNewswire) +6.15%
May-04-22 04:01PM	Rezolute to Host Corporate Update Call on May 4, 2022 (GlobeNewswire)

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The firm's antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada in March 2010 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hogenhuis Wladimir	Director	Dec 16 '25	Buy	1.69	5,650	9,548	119,675	Dec 17 04:14 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Dec 16 '25	Buy	1.70	28,000	47,600	308,352	Dec 17 04:13 PM
Evans Daron	CFO	Dec 15 '25	Buy	1.77	40,000	70,640	415,900	Dec 15 07:35 PM
Evans Daron	CFO	Dec 15 '25	Buy	1.79	5,000	8,938	7,000	Dec 15 07:35 PM
Elam Nevan C	CEO	Dec 15 '25	Buy	1.59	32,000	50,880	641,119	Dec 15 07:35 PM
Karnawat Sunil Ratilal	Chief Commercial Officer	Dec 15 '25	Buy	1.62	12,100	19,599	71,542	Dec 15 07:34 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Jun 25 '25	Buy	4.38	2,500	10,939	15,500	Jun 26 09:07 AM
Evans Daron	CFO	Jun 24 '25	Buy	4.05	5,000	20,250	268,900	Jun 24 12:41 PM
Kim Young-Jin	Director	Jun 13 '25	Buy	3.25	1,230,769	3,999,999	8,423,386	Jun 23 09:38 AM
KREHER NERISSA	Director	Jun 13 '25	Buy	3.25	3,076	9,997	37,576	Jun 23 09:12 AM
Hogenhuis Wladimir	Director	Mar 31 '25	Buy	2.92	6,758	19,733	84,025	Apr 01 03:52 PM
Elam Nevan C	CEO	Mar 27 '25	Buy	2.85	12,302	34,999	224,119	Mar 31 09:18 AM
Evans Daron	CFO	Mar 26 '25	Buy	2.89	10,000	28,900	237,900	Mar 28 08:40 AM
Evans Daron	CFO	Mar 26 '25	Buy	2.88	10,000	28,800	23,000	Mar 28 08:40 AM
Hogenhuis Wladimir	Director	Feb 18 '25	Buy	4.70	10,000	47,000	77,267	Feb 20 07:59 PM
Evans Daron	CFO	Dec 09 '25	Buy	5.04	10,549	53,167	131,900	Dec 10 09:11 AM

Open in Screener

SVRA

Savara Inc

Feb 11 • 04:00PM ET

5.35

+0.08 1.52 %

Healthcare • Biotechnology • USA • NASD

Peers: BMRN RARE ARWR NVAX AXSM HRTX ACAD PTGX KPTI CRBP

| Held by: VTI IWM VXF XBI IWO VTWO IBB SCHA LFSC IWC

Index	RUT	P/E	-	EPS (ttm)	-0.54	Insider Own	49.66%	Shs Outstand	172.85M	Perf Week	-0.19%
Market Cap	1.09B	Forward P/E	-	EPS next Y	-0.44	Insider Trans	-0.02%	Shs Float	102.42M	Perf Month	-7.28%
Enterprise Value	994.00M	PEG	-	EPS next Q	-0.12	Inst Own	39.00%	Short Float	20.47%	Perf Quarter	33.75%
Income	-115.64M	P/S	-	EPS this Y	-7.26%	Inst Trans	-0.98%	Short Ratio	8.31	Perf Half Y	107.36%
Sales	0.00M	P/B	9.80	EPS next Y	14.54%	ROA	-60.91%	Short Interest	20.96M	Perf YTD	-11.28%
Book/sh	0.55	P/C	8.75	EPS next 5Y	38.07%	ROE	-78.74%	52W High	7.01 -23.63%	Perf Year	94.55%
Cash/sh	0.61	P/FCF	-	EPS past 3/5Y	-14.63% 24.35%	ROIC	-93.14%	52W Low	1.89 183.07%	Perf 3Y	119.26%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.27% 5.65%	Perf 5Y	198.88%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-22.39%	Oper. Margin	-	ATR (14)	0.33	Perf 10Y	-67.49%
Dividend Ex-Date	-	Quick Ratio	7.65	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	42.93	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.65	EPS Q/Q	-19.30%	SMA20	-5.65%	Beta	0.33	Target Price	10.81
Payout	-	Debt/Eq	0.32	Sales Q/Q	-	SMA50	-10.59%	Rel Volume	0.49	Prev Close	5.27
Employees	59	LT Debt/Eq	0.32	Earnings	Nov 12 AMC	SMA200	37.57%	Avg Volume	2.52M	Price	5.35
IPO	Oct 16, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.66% -	Trades		Volume	1,242,109	Change	1.52%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$7
Aug-15-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
May-29-25	Downgrade	H.C. Wainwright	Buy → Neutral	$2
Dec-20-24	Initiated	Wells Fargo	Overweight	$8
Nov-13-24	Downgrade	Evercore ISI	Outperform → In-line	$7 → $5
Feb-15-24	Initiated	JMP Securities	Mkt Outperform	$8
Nov-07-23	Initiated	Guggenheim	Buy	$7
May-16-23	Upgrade	Jefferies	Hold → Buy	$2 → $4
Mar-31-23	Downgrade	Jefferies	Buy → Hold	$2
Mar-16-21	Initiated	Piper Sandler	Overweight	$7
Mar-15-21	Initiated	Oppenheimer	Outperform	$4
Jun-13-19	Reiterated	H.C. Wainwright	Buy	$22 → $6
Jun-13-19	Downgrade	Ladenburg Thalmann	Buy → Neutral	$21 → $3
Jun-13-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-13-18	Resumed	ROTH Capital	Neutral	$12
Jan-03-18	Initiated	Ladenburg Thalmann	Buy	$35
Sep-27-17	Resumed	ROTH Capital	Buy	$40
Sep-22-17	Initiated	Jefferies	Buy	$20
Sep-11-17	Initiated	JMP Securities	Mkt Outperform	$20

Show Previous Ratings

Feb-04-26 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) -5.30%
Jan-27-26 08:05AM	Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* (Business Wire)
Jan-16-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-08-26 04:05PM	PANTHERx Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* (Business Wire)
Dec-22-25 08:30AM	Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire) +6.94%
08:05AM	Loading…
Dec-17-25 08:05AM	Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-11-25 08:05AM	Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* (Business Wire)
Dec-02-25 08:05AM	Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow Nebulizer System (Business Wire)
Dec-01-25 01:23PM	Savara (SVRA) Climbs 27.8% Ahead of 2 Health Conferences (Insider Monkey) -7.15%
Nov-20-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) +5.35%
Nov-12-25 04:05PM	Savara Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-03-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire)
02:56AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-31-25 04:05PM	Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M (Business Wire)
Oct-30-25 11:29PM	What Does Wall Street Think About Savara Inc. (SVRA)? (Insider Monkey)
09:43PM	Loading…
Oct-29-25 09:43PM	Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants (Business Wire)
04:07PM	Savara Announces Proposed Public Offering (Business Wire)
04:01PM	Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
11:57AM	Savara Inc. (SVRA) To Present Molgramostim Data in the Fight Against Infections (Insider Monkey)
Oct-17-25 08:05AM	Savara Announces Chief Medical Officer (CMO) Transition (Business Wire)
Oct-13-25 04:59PM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-10-25 09:00AM	Savara Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SVRA (PR Newswire)
Oct-07-25 07:40AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-02-25 04:05PM	Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025 (Business Wire)
Sep-29-25 02:00AM	Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 (Business Wire)
Sep-25-25 04:37PM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Sep-24-25 04:25PM	Did You Lose Money on Savara Inc. (SVRA)? Levi & Korsinsky Urges Investors to Act Before November 7, 2025 (Newsfile)
Sep-23-25 10:53AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights SVRA (Business Wire)
Sep-20-25 02:43AM	Guggenheim Lifts Savara (SVRA) Price Target on Pulmonary Alveolar Proteinosis Opportunity (Insider Monkey)
Sep-11-25 04:18PM	Investors in Savara Inc. (SVRA): Protect Your Rights - Contact Levi & Korsinsky Before November 7, 2025 (Newsfile) -6.27%
09:00AM	Loading…
Sep-02-25 09:00AM	Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis (Business Wire)
Aug-26-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) +5.41%
Aug-23-25 04:16AM	Savara Inc. (SVRA) Upgraded to Buy After FDA CMC Breakthrough (Insider Monkey)
Aug-20-25 05:15PM	New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Aug-18-25 08:05AM	Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025 (Business Wire)
Aug-13-25 08:05AM	Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
Jul-18-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-27-25 08:05AM	Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) (Business Wire) -31.69%
07:53AM	Biogen strikes RNAi deal with City; Aurion withdraws IPO (BioPharma Dive)
May-23-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-22-25 09:05AM	Savara Announces Participation in Jefferies Global Healthcare Conference (Business Wire)
May-21-25 11:16AM	Savara Inc. (SVRA): Analysts See 212% Upside Potential (Insider Monkey) -7.18%
May-18-25 02:30PM	Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025 (Business Wire)
May-13-25 04:05PM	Savara Reports First Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
May-12-25 04:05PM	Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference (Business Wire) +5.59%
May-01-25 04:05PM	Savara Announces Participation in the Upcoming Citizens Life Sciences Conference (Business Wire)
Apr-21-25 11:16AM	Savara: Make-It-Or-Break-It Molbreevi BLA Filing (Seeking Alpha)
Apr-11-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) +10.61%
Apr-07-25 04:05PM	Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences (Business Wire) -5.45%
Mar-27-25 07:05AM	Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update (Business Wire)
Mar-26-25 04:45PM	Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital (Business Wire)
04:05PM	Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-17-25 08:05AM	Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025 (Business Wire) +7.66%
Mar-06-25 08:05AM	Savara Announces U.S. Launch of the aPAP ClearPath Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-03-25 04:15PM	Savara Announces Participation in the Leerink Global Healthcare Conference (Business Wire) -6.83%
Feb-14-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-30-25 08:39AM	Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research (Business Wire)
Jan-29-25 04:05PM	Savara Announces Participation in Upcoming Healthcare Investor Conferences (Business Wire)
Dec-23-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Dec-18-24 04:05PM	Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire) -6.21% +6.95%
Dec-17-24 04:05PM	Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 (Business Wire)
Nov-13-24 01:21PM	Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate (GuruFocus.com) -15.14%
08:05AM	Savara Announces Participation in Upcoming Healthcare Conferences (Business Wire)
Nov-12-24 08:05AM	Savara Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) -5.90%
Nov-04-24 04:05PM	Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference (Business Wire)
Oct-22-24 08:05AM	Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of The Balancing Act Airing on Lifetime TV (Business Wire)
Oct-18-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.05%
Oct-01-24 08:05AM	Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting (Business Wire) -5.90%
Sep-27-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Sep-24-24 08:05AM	Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately (Business Wire)
Sep-23-24 08:05AM	Savara to Host Analyst and Investor Webinar on September 30, 2024 (Business Wire)
Sep-08-24 06:45AM	Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 (Business Wire)
Sep-06-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Sep-03-24 04:05PM	Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Sep-01-24 10:26PM	Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
Aug-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Aug-15-24 08:05AM	Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 (Business Wire) +5.87%
Aug-12-24 04:05PM	Savara Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jun-29-24 08:35PM	Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-28-24 08:50AM	Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock (Business Wire) +5.77%
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
06:30AM	Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-25-24 08:05PM	Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-19-24 09:00AM	3 Penny Stocks Poised for Major Upside Over the Next 5 Years (InvestorPlace)
Jun-11-24 06:00AM	3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition (InvestorPlace)
May-29-24 08:05AM	Savara to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 08:20AM	Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating (MT Newswires)
May-19-24 12:15PM	Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
May-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.08%
May-09-24 10:55PM	SVRA Stock Earnings: Savara Misses EPS for Q1 2024 (InvestorPlace) -8.19%
04:05PM	Savara Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-07-24 04:05PM	Savara to Present at the Citizens JMP Life Sciences Conference (Business Wire) +6.26% -5.13%
Apr-08-24 08:05AM	Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
Mar-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Mar-07-24 10:54PM	SVRA Stock Earnings: Savara Beats EPS for Q4 2023 (InvestorPlace) -5.19%

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RAMSAY DAVID A	Director	Dec 19 '25	Sale	6.06	20,000	121,220	2,533,642	Dec 19 05:00 PM
RAMSAY DAVID A	Director	Dec 18 '25	Proposed Sale	6.11	20,000	122,200		Dec 18 11:17 AM
Elam Nevan C	Director	Dec 02 '25	Option Exercise	1.46	5,860	8,556	68,360	Dec 04 06:55 PM
Hawkins Richard J	Director	Nov 14 '25	Option Exercise	1.46	5,860	8,556	121,326	Nov 17 04:38 PM
Hawkins Richard J	Director	Jun 20 '25	Buy	2.04	48,225	98,572	115,466	Jun 23 02:39 PM
McCracken Joseph S	Director	May 29 '25	Buy	2.08	10,000	20,825	260,837	Jun 02 07:59 AM
RAMSAY DAVID A	Director	Mar 31 '25	Buy	2.77	150,000	416,250	2,513,642	Apr 01 07:00 AM

RZLT

Rezolute Inc

SVRA

Savara Inc

Upgrade your FINVIZ experience